Home

EVAg

European Virus Archive - GLOBAL
  • Contact Us
  • FAQs
  • Login / Register
  • RSS
  • Facebook
  • Twitter
  • Linkedin
  • Youtube
  • Home
  • Portal
  • The project
    • Concept & Approach
    • ABS Strategy
    • DURC issues
    • News
    • Publications
    • Newsletters
  • Partners
  • Industrials
  • Home
  • Site Map

Site Map

If you are lost on our website, this page might help you to locate the page you need:

Sitemap

  • Home
  • Our Partners
  • The EVAg project
  • FAQs
  • Contact
  • Legal mentions
  • Your EVAg account
  • EVAg Portal main page

Product categories

EVAg product categories
  • Virus
    • Cultivable virus
    • Uncultivable virus
    • Inactivated virus
  • Derived product
    • Protein
    • Nucleic Acid
      • PCR products
      • Infectious Subgenomic Amplicon
      • In Vitro Transcript
      • Viral RNA
      • Cloned nucleic acid
        • Bulk positive control
        • Expression plasmid
        • DNA template for recombinant virus or replicon
    • Antibody or Hybridoma
      • Antibody
      • Hybridoma
    • Antigen
    • Diagnostic reagent
    • Detection Kit (for RUO)
      • Molecular detection kit
      • Proficiency test
      • ELISA
      • IFA
    • Bundle
    • Service
Hotline

EVAg Hotline

Any institution that requires guidance on the actions that should be taken for recording, reporting, investigating security breaches and to ensure the safety of all staff, can be supported by EVAg

For tropical and RG4 viruses

In the event of a major biological incident regarding tropical (exotic) viruses or Risk Group 4 viruses, contact

Bernard Nocht Institute by clicking here

For other human viruses of medical importance

The Charité University Berlin (CUB) is in charge of our hotline dedicated to other human viruses of medical importance

Contact the CUB here

For veterinary pathogens of economic importance

In case of biological events involving such pathogens contact
The Animal and Plant Health Agency here

or
+44 1932 357840

EVAg

This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 871029


H2020 - grant agreement n°871029-EVA-GLOBAL
  • FAQs
  • Sitemap
  • Legal mentions
  • Newsletter
  • Contact
  • RSS
  • Facebook
  • Twitter
  • Linkedin
  • Youtube
The EVA-GLOBAL community supports fair and equitable benefit sharing as conceived in various United Nations frameworks. The consortium is actively implementing a CBD/Nagoya Protocol compliance strategy. Learn more ...

Yes, we also use cookies on this site to enhance your user experience

By clicking the Accept button, you agree to us doing so for all our categories of cookies.

Strictly necessary cookies for our website to be able to operate or to provide you with essential services such as connecting to your account on this website.
Cookies that mainly permit to remember settings you have applied. They help our site to work well and enable additional features which can make your user experience better.
Cookies that permit to use the social media sharing buttons on our Website.
Cookies to measure the visits on our Website and permit to analyze how the Website is accessed, used, or is performing.